Product Name |
Code |
Species Reactivity |
Application |
Size |
---|---|---|---|---|
TNNT2 Recombinant Monoclonal Antibody |
CSB-RA058699A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
LCP1 Recombinant Monoclonal Antibody |
CSB-RA188599A0HU | Human | ELISA, FC | 100μl/50μl |
GAA Recombinant Monoclonal Antibody |
CSB-RA566370A0HU | Human | ELISA, IHC | 100μl/50μl |
GLA Recombinant Monoclonal Antibody |
CSB-RA950991A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
SIRPA Recombinant Monoclonal Antibody |
CSB-RA443117A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
IL8 Recombinant Monoclonal Antibody |
CSB-RA582227A0HU | Human | ELISA, FC | 100μl/50μl |
AGO2 Recombinant Monoclonal Antibody |
CSB-RA965823A0HU | Human | ELISA, IF, FC | 100μl/50μl |
PLAT Recombinant Monoclonal Antibody |
CSB-RA778654A0HU | Human | ELISA, FC | 100μl/50μl |
MYO7A Recombinant Monoclonal Antibody |
CSB-RA250599A0HU | Human | ELISA, FC | 100μl/50μl |
Phospho-MAPT (S202) Recombinant Monoclonal Antibody |
CSB-RA082445A0HU | Human | ELISA, FC | 100μl/50μl |
Phospho-MAPT (S214) Recombinant Monoclonal Antibody |
CSB-RA050476A0HU | Human | ELISA, IHC | 100μl/50μl |
Phospho-MAPT (S404) Recombinant Monoclonal Antibody |
CSB-RA901354A0HU | Human | ELISA, IHC | 100μl/50μl |
Phospho-MAPT (S199) Recombinant Monoclonal Antibody |
CSB-RA051594A0HU | Human | ELISA, IHC, FC | 100μl/50μl |
CD247 Recombinant Monoclonal Antibody |
CSB-RA244537A0HU | Human | ELISA, FC | 100μl/50μl |
TK1 Recombinant Monoclonal Antibody |
CSB-RA931459A0HU | Human | ELISA, WB, IF, FC | 100μl/50μl |
WFDC2 Recombinant Monoclonal Antibody |
CSB-RA964489A0HU | Human | ELISA, WB, FC | 100μl/50μl |
Formyl-HIST1H3A (K122) Recombinant Monoclonal Antibody |
CSB-RA148519A0HU | Human | ELISA, IHC | 100μl/50μl |
Mutated-HIST1H3A (K27) Recombinant Monoclonal Antibody |
CSB-RA943659A0HU | Human | ELISA, IHC | 100μl/50μl |
Acetyl-HIST1H3A Recombinant Monoclonal Antibody |
CSB-RA547773A0HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
Mono-methyl-HIST1H3A (K9) Recombinant Monoclonal Antibody |
CSB-RA792403A0HU | Human | ELISA, IHC, IF, FC | 100μl/50μl |
ERBB2 Recombinant Monoclonal Antibody |
CSB-RA007763MA1HU | Human | ELISA | 100μl/50μl |
CEACAM5/CEACAM6 Recombinant Monoclonal Antibody |
CSB-RA005165MA2HU | Human | ELISA | 100μl/50μl |
CLDN3 Recombinant Monoclonal Antibody |
CSB-RA005505MA1HU | Human | ELISA | 100μl/50μl |
TPBG Recombinant Monoclonal Antibody |
CSB-RA024093MA1HU | Human, Macaca mulatta | ELISA | 100μl/50μl |
IL12&IL23 Recombinant Monoclonal Antibody |
CSB-RA011587MA1HU | Human | ELISA | 100μl/50μl |
PROM1 Recombinant Monoclonal Antibody |
CSB-RA018751MA1HU | Human | ELISA | 100μl/50μl |
TMEFF2 Recombinant Monoclonal Antibody |
CSB-RA883439MA1HU | Human | ELISA | 100μl/50μl |
GLP1R Recombinant Monoclonal Antibody |
CSB-RA009514MA1HU | Human | ELISA, FC | 100μl/50μl |
LY6G6D Recombinant Monoclonal Antibody |
CSB-RA013246MA1HU | Human, Macaca fascicularis | ELISA, FC | 100μl/50μl |
PD-1 Recombinant Monoclonal Antibody |
CSB-RA619964MA1HU | Human | ELISA | 100μl/50μl |
TROP2 Recombinant Monoclonal Antibody |
CSB-RA023072MA1HU | Human | ELISA | 100μl/50μl |
IL17A Recombinant Monoclonal Antibody |
CSB-RA624104MA1HU | Human | ELISA | 100μl/50μl |
VSIG4 Recombinant Monoclonal Antibody |
CSB-RA896869MA1HU | Human | ELISA | 100μl/50μl |
SLC39A6 Recombinant Monoclonal Antibody |
CSB-RA621669MA1HU | Human | ELISA | 100μl/50μl |
CCR8 Recombinant Monoclonal Antibody |
CSB-RA004847MA4HU | Human | FC | 100μl/50μl |
CLDN6/9 Recombinant Monoclonal Antibody |
CSB-RA005508MA1HU | Human | ELISA,FC | 100μl/50μl |
CLDN4 Recombinant Monoclonal Antibody |
CSB-RA005506MA1HU | Human | ELISA | 100μl/50μl |
DDR1 Recombinant Monoclonal Antibody |
CSB-RA006595MA1HU | Human | ELISA | 100μl/50μl |
ZG16B Recombinant Monoclonal Antibody |
CSB-RA836195MA1HU | Human, Macaca fascicularis | ELISA | 100μl/50μl |
MS4A1 Recombinant Monoclonal Antibody |
CSB-RA015007MA3HU | Human, Dog, Macaca fascicularis | ELISA | 100μl/50μl |
GPC3 Recombinant Monoclonal Antibody |
CSB-RA009705A1HU | Human | ELISA | 100μl/50μl |
ENPP3 Recombinant Monoclonal Antibody |
CSB-RA007681MA1HU | Human, Macaca fascicularis | ELISA,FC | 100μl/50μl |
CNR1 Recombinant Monoclonal Antibody |
CSB-RA005678MA01HU | Human | ELISA | 100μl/50μl |
MYLK Recombinant Monoclonal Antibody |
CSB-RA145619A0HU | Human | ELISA, WB, FC | 100μl/50μl |
LMO2 Recombinant Monoclonal Antibody |
CSB-RA825959A0HU | Human | ELISA, WB | 100μl/50μl |
SLC2A3 Recombinant Monoclonal Antibody |
CSB-RA162667A0HU | Human | ELISA, WB, IHC, FC | 100μl/50μl |
ULBP1 Recombinant Monoclonal Antibody |
CSB-RA446786A0HU | Human | ELISA, WB | 100μl/50μl |
SRR Recombinant Monoclonal Antibody |
CSB-RA945827A0HU | Human | ELISA, WB, FC | 100μl/50μl |
SLC27A4 Recombinant Monoclonal Antibody |
CSB-RA235828A0HU | Human, Mouse | ELISA, WB | 100μl/50μl |
SLC25A12 Recombinant Monoclonal Antibody |
CSB-RA912385A0HU | Human | ELISA, WB | 100μl/50μl |
A stable and highly specific antibody plays an important role in obtaining real and repeatable experimental results. It is a big headache if the antibody used in the experiment does not work. And what's even worse is that you use the antibodies to repeat the same experiment but get inconsistent results.
It is estimated that the annual loss in research funding due to the use of antibodies without enough validation is about $ 800 million worldwide. At the same time, it has caused countless experimental failures, and a waste of precious samples and researchers'youth.
Nowadays, the antibody validations information provided by antibody manufacturers and academic articles is very helpful for you to select high-quality antibodies. However, there is still an inevitable problem: whether it is polyclonal antibodies extracted from animal serum or monoclonal antibodies produced by hybridomas, there are more or fewer differences between batches. And recombinant antibodies may finally solve this problem.
Recombinant antibodies refers to the application of molecular cloning and gene mutation technology to transform a gene coding sequence of an antibody to produce superior performance of antibodies, also known as genetically engineered antibodies. Comparing with monoclonal antibodies generated in vivo of living animals through hybridoma technology, recombinant antibodies are a type of monoclonal antibodies which are produced in vitro by using synthetic genes.
In recent years, the use of recombinant antibodies is becoming increasingly wider and deeper in both therapeutics and diagnostics. With significant advantages over conventional antibodies, recombinant antibodies become more and more favored. The most important point is that recombinant antibodies can maximize the humanization to solve the heterogeneity between different species.
Generally speaking, recombinant antibodies can be divided into three classes, including chimeric antibody, humanized antibody, fully humanized antibody and small molecular antibody.
Compared with traditional antibodies, recombinant antibodies have the advantages of being irresistible, which is one of the reasons for their gradually emerging. Here, we present the advantages one by one as follows:
Because recombinant antibodies have these unprecedented advantages, recombinant antibodies fulfill a large spectrum of functions spanning from research to diagnosis and treatment therapies for various diseases. Their specificity and low immunogenicity make them a great alternative to traditional forms of treatment, increasing the accuracy of targeting specific molecules and avoiding adverse side effects.
Additionally, for recombinant antibodies production, it follows principally similar workflow. Generally, it consists of five steps: the construction of antibody gene library, phage display, the separation of antibodies, the modification of the isolated antibodies, and the scaling up of the production of selected antibodies in the cell culture expression system.
Although the processes of recombinant antibodies production are same as workflow, we need to recognize that there are several obstacles to the production of recombinant antibodies, such as lower antibody production, and highly trained and experienced technicians. Due to the complexity and intensive high technology of recombinant antibody production, most scientists need to obtain them from outsourcing companies.
Read the article, The Overview of Recombinant Antibody, for more information.
S Antibody referenced in "A magneto-optical biochip for rapid assay based on the Cotton–Mouton effect of γ-Fe2O3@ Au core/shell nanoparticles", Journal of nanobiotechnology, 2021.
SARS-CoV-2 Spike RBD Nanobody referenced in "Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2", Bioorganic & Medicinal Chemistry, 2021.
HIF1A Antibody, CASP3 Antibody referenced in "PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia", Cancer cell international, 2021.
Phospho-ERN1 (S724) Antibody referenced in "The ER stress sensor inositol-requiring enzyme 1α in Kupffer cells promotes hepatic ischemia-reperfusion injury", Journal of Biological Chemistry, 2021.
CDK4 Antibody and CDK6 Antibody referenced in "Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells Via Forkhead Box M1 Suppression", Journal of Cancer, 2021.
BIRC5 Antibody referenced in "LTBP4 Inhibits the Proliferation and Metastasis in Melanoma by Activating Hippo-YAP Signaling", Research Square, 2020.